{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:04:56Z","timestamp":1779955496724,"version":"3.53.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcf.2025.04.007","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:45:51Z","timestamp":1746060351000},"page":"843-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6858","authenticated-orcid":false,"given":"Jonathan D.","family":"Cogen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-4357","authenticated-orcid":false,"given":"Jane","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6070-9738","authenticated-orcid":false,"given":"Michael R.","family":"Kosorok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-8451","authenticated-orcid":false,"given":"Stephanie Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne S.","family":"Muhlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jcf.2025.04.007_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.04.007_bib0002","article-title":"Canadian consensus statement on aerosolized antibiotic use in cystic fibrosis","year":"2020","journal-title":"Cystic Fibr Can"},{"key":"10.1016\/j.jcf.2025.04.007_bib0003","first-page":"S1569","article-title":"Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S","volume":"24","author":"Muhlebach","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.007_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.04.007_bib0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. The ELITE Trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.04.007_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2025.04.007_bib0007","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis","volume":"11","author":"Smith","year":"2022","journal-title":"Cochr Datab Systemat Rev"},{"issue":"6","key":"10.1016\/j.jcf.2025.04.007_bib0008","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciab208","article-title":"Association of intensity of antipseudomonal antibiotic therapy with risk of treatment-emergent organisms in children with cystic fibrosis and newly acquired Pseudomonas aeruginosa","volume":"73","author":"Cogen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcf.2025.04.007_bib0009","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcf.2018.01.008","article-title":"Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis","volume":"17","author":"Hong","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.007_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.04.007_bib0011","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the Global Lung Function 2021 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2025.04.007_bib0012","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.007_bib0013","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2015","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcf.2025.04.007_bib0014","doi-asserted-by":"crossref","first-page":"e5931","DOI":"10.7717\/peerj.5931","article-title":"Interaction between Pseudomonas aeruginosa and Aspergillus fumigatus in cystic fibrosis","volume":"6","author":"Zhao","year":"2018","journal-title":"Peer J"},{"issue":"3","key":"10.1016\/j.jcf.2025.04.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150155","article-title":"Biofilm filtrates of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients inhibit preformed Aspergillus fumigatus biofilms via apoptosis","volume":"11","author":"Shirazi","year":"2016","journal-title":"PloS ONE"},{"key":"10.1016\/j.jcf.2025.04.007_bib0016","doi-asserted-by":"crossref","unstructured":"Bargon J., Dauletbaev D., Kohler B., Wolf M., Posselt H.G., Wagner T.O.F. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 199; 93: 835\u20138.","DOI":"10.1016\/S0954-6111(99)90270-6"},{"key":"10.1016\/j.jcf.2025.04.007_bib0017","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcf.2018.01.008","article-title":"Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis","volume":"17","author":"Hong","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German cystic fibrosis patients and impact on lung function","volume":"10","author":"Duesberg","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.007_bib0019","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12890-022-02054-3","article-title":"Persistent Aspergillus fumigatus Infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study","volume":"22","author":"Blomquist","year":"2022","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.007_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The Effect of Chronic Infection With Aspergillus fumigatus on Lung Function and Hospitalization in Patient with Cystic Fibrosis","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jcf.2025.04.007_bib0021","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1164\/rccm.201908-1585OC","article-title":"Aspergillus infections and progression of structural lung disease in children with cystic fibrosis","volume":"201","author":"Breuer","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.04.007_bib0022","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jcf.2019.08.008","article-title":"The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis","volume":"19","author":"Hong","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.04.007_bib0023","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic pseudomonas aeruginosa infection\u2014a European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.007_bib0024","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q","article-title":"Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis","volume":"30","author":"Talmaciu","year":"2000","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.04.007_bib0025","doi-asserted-by":"crossref","unstructured":"Denton M., Todd N.J., Littlewood J.M. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 15(5): 402\u20135.","DOI":"10.1007\/BF01690098"},{"issue":"6","key":"10.1016\/j.jcf.2025.04.007_bib0026","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1378\/chest.121.6.1754","article-title":"Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis","volume":"121","author":"Graff","year":"2002","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.jcf.2025.04.007_bib0027","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.52586\/5054","article-title":"What is the role of Achromobacter species in patients with cystic fibrosis?","volume":"26","author":"Esposito","year":"2021","journal-title":"Front Biosci-Landm"},{"key":"10.1016\/j.jcf.2025.04.007_bib0028","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/crj.12278","article-title":"Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis","volume":"10","author":"Yang","year":"2016","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jcf.2025.04.007_bib0029","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/01.inf.0000202126.44544.41","article-title":"Inhaled tobramycin-associated hearing loss in an adolescent with renal failure","volume":"25","author":"Patatanian","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jcf.2025.04.007_bib0030","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1542-4758.2012.00675.x","article-title":"Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis","volume":"16","author":"Florescu","year":"2012","journal-title":"Hemodialy Int"},{"key":"10.1016\/j.jcf.2025.04.007_bib0031","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ppul.10185","article-title":"Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy","volume":"34","author":"Hoffman","year":"2022","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:36:24Z","timestamp":1779953784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1569199325014626"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.007","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}